Big Pharma Is Taking Advantage of Type One Diabetics

When there are a lot of entrenched monetary interests in play, things get dicey. Like with type 1 diabetics. There's 1.8 million of them in the country. The average annual expenditure is 27,500 bucks per patient, which accounts for $49.5 billion of annual revenue to companies, right? Mostly pharma companies for production of insulin and peripheral material. The patients want it gone, the people who are impinged biologically because of that want it gone. But the guys who are tracking billions of dollars to their bottom line, they 100% do not want anything, right? We called it the inhale challenge. And we had, you know, versa climbers and treadmills and things like that. We were getting people's heart rates up to about 150, 160bpm and then having them drink a can and their heart rate within about a minute and minute and a half would drop back down in a normal range. That was just leveraging what I had done accidentally on my own. It was just kind of like, how do you explain to people what the effect really is?